Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.
In rare cases of differentiated thyroid carcinoma (DTC), radioiodine treatment is no longer effective due to cell dedifferentiation. Targeting somatostatin receptors in DTC cells by radiolabelled somatostatin analogues could provide an alternative therapy option. The aim of this study was to evaluate safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with advanced, non-iodine avid DTC. Eleven patients aged 47-81 years (median: 65 years) with a history of several courses of radioiodine therapy, increasing thyroglobulin (Tg) and negative whole body scan, were qualified to the study. After confirming receptor expression by somatostatin receptor scintigraphy, PRRT with yttrium-90 labelled analogue was initiated. Fractionated treatment protocol was used with four doses of (90)Y-DOTA-TOC in 12-week intervals. Activity of each dose was 3.7 GBq (100 mCi). Of 11 patients, 5 died before receiving the fourth course of PRRT. In the remaining six patients, morphological response, evaluated 3 months after the last course using RECIST criteria showed partial remission (PR) in one patient, stable disease (SD) in two patients and progressive disease (PD) in three patients. Biochemical response based on Tg measurements before and after PRRT showed PR in one patient, SD in four patients and PD in one patient. Median survival was 21 months from the first course of PRRT. Only minor and transient hematological toxicity was observed in some patients. We conclude that PRRT is generally well-tolerated and may be a valuable option for some patients with radioiodine-refractory DTC.
Department of Endocrinology, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznań, Poland, rafal.czepczynski@gmail.com.
Rafał
R
Czepczyński
Magdalena
M
Matysiak-Grześ
Maria
M
Gryczyńska
Maciej
M
Bączyk
Anna
A
Wyszomirska
Marek
M
Stajgis
Marek
M
Ruchała
D000368:Aged; D000369:Aged, 80 and over; D063646:Carcinogenesis; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy*; D002454:Cell Differentiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D015282:Octreotide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000819:agonists*; D012189:Retrospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D016896:Treatment Outcome
D017481:Receptors, Somatostatin; D013004:Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide